Berzofsky JA - Search Results

1

The combination of GM-CSF and IL-2 as local adjuvant shows synergy in enhancing peptide vaccines and provides long term tumor protection.

Toubaji A, Hill S, Terabe M, Qian J, Floyd T, Simpson RM, Berzofsky JA, Khleif SN. Toubaji A, et al. Among authors: berzofsky ja. Vaccine. 2007 Aug 1;25(31):5882-91. doi: 10.1016/j.vaccine.2007.05.040. Epub 2007 Jun 12. Vaccine. 2007. PMID: 17602804

2

Features of T-cell recognition and antigen structure useful in the design of vaccines to elicit T-cell immunity.

Berzofsky JA. Berzofsky JA. Vaccine. 1988 Apr;6(2):89-93. doi: 10.1016/s0264-410x(88)80005-7. Vaccine. 1988. PMID: 2455388 Review.

3

Cytokine-in-adjuvant steering of the immune response phenotype to HIV-1 vaccine constructs: granulocyte-macrophage colony-stimulating factor and TNF-alpha synergize with IL-12 to enhance induction of cytotoxic T lymphocytes.

Ahlers JD, Dunlop N, Alling DW, Nara PL, Berzofsky JA. Ahlers JD, et al. Among authors: berzofsky ja. J Immunol. 1997 Apr 15;158(8):3947-58. J Immunol. 1997. PMID: 9103465

4

A model for CD8+ CTL tumor immunosurveillance and regulation of tumor escape by CD4 T cells through an effect on quality of CTL.

Matsui S, Ahlers JD, Vortmeyer AO, Terabe M, Tsukui T, Carbone DP, Liotta LA, Berzofsky JA. Matsui S, et al. Among authors: berzofsky ja. J Immunol. 1999 Jul 1;163(1):184-93. J Immunol. 1999. PMID: 10384115

5

Interplay of cytokines and adjuvants in the regulation of mucosal and systemic HIV-specific CTL.

Belyakov IM, Ahlers JD, Clements JD, Strober W, Berzofsky JA. Belyakov IM, et al. Among authors: berzofsky ja. J Immunol. 2000 Dec 1;165(11):6454-62. doi: 10.4049/jimmunol.165.11.6454. J Immunol. 2000. PMID: 11086085

6

NKT cell-mediated repression of tumor immunosurveillance by IL-13 and the IL-4R-STAT6 pathway.

Terabe M, Matsui S, Noben-Trauth N, Chen H, Watson C, Donaldson DD, Carbone DP, Paul WE, Berzofsky JA. Terabe M, et al. Among authors: berzofsky ja. Nat Immunol. 2000 Dec;1(6):515-20. doi: 10.1038/82771. Nat Immunol. 2000. PMID: 11101874

7

Clinical trial designs for the early clinical development of therapeutic cancer vaccines.

Simon RM, Steinberg SM, Hamilton M, Hildesheim A, Khleif S, Kwak LW, Mackall CL, Schlom J, Topalian SL, Berzofsky JA. Simon RM, et al. Among authors: berzofsky ja. J Clin Oncol. 2001 Mar 15;19(6):1848-54. doi: 10.1200/JCO.2001.19.6.1848. J Clin Oncol. 2001. PMID: 11251017

8

Mechanisms of cytokine synergy essential for vaccine protection against viral challenge.

Ahlers JD, Belyakov IM, Matsui S, Berzofsky JA. Ahlers JD, et al. Among authors: berzofsky ja. Int Immunol. 2001 Jul;13(7):897-908. doi: 10.1093/intimm/13.7.897. Int Immunol. 2001. PMID: 11431420

9

A push-pull approach to maximize vaccine efficacy: abrogating suppression with an IL-13 inhibitor while augmenting help with granulocyte/macrophage colony-stimulating factor and CD40L.

Ahlers JD, Belyakov IM, Terabe M, Koka R, Donaldson DD, Thomas EK, Berzofsky JA. Ahlers JD, et al. Among authors: berzofsky ja. Proc Natl Acad Sci U S A. 2002 Oct 1;99(20):13020-5. doi: 10.1073/pnas.192251199. Epub 2002 Sep 13. Proc Natl Acad Sci U S A. 2002. PMID: 12232042 Free PMC article.

10

Resistance to metastatic disease in STAT6-deficient mice requires hemopoietic and nonhemopoietic cells and is IFN-gamma dependent.

Ostrand-Rosenberg S, Clements VK, Terabe M, Park JM, Berzofsky JA, Dissanayake SK. Ostrand-Rosenberg S, et al. Among authors: berzofsky ja. J Immunol. 2002 Nov 15;169(10):5796-804. doi: 10.4049/jimmunol.169.10.5796. J Immunol. 2002. PMID: 12421960

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

469 results

Search Page

Filters